Background Decreased kidney function and greater albuminuria are associated with increased incidence and extent of coronary artery calcium (CAC). We investigated whether the associations between kidney function and urine protein-tocreatinine ratio (UPCR) with CAC differ by HIV serostatus.
Background
Coronary artery calcium (CAC) represents evidence of atherosclerotic plaque and predicts risk for both myocardial infarction and death from cardiovascular disease (CVD) [1] . Decreased kidney function has been associated with both incidence and extent of CAC [2, 3] . In fact, chronic kidney disease (CKD) is an independent predictor of cardiovascular events. Emerging evidence in the general population suggests that individuals with predialysis CKD are more likely to die from CVD than from kidney disease [4] . In addition, albuminuria, an indicator of endothelial dysfunction, has been shown to be associated both with incident CAC in a large population-based cohort study [5] and an independent predictor of cardiovascular mortality across diverse, HIVuninfected populations [6] .
HIV infection is associated with increased risk of acute myocardial infarction [7] and CAC progression [8] . CKD is an important complication of HIV infection and occurs in up to 30% of infected patients [9] . Using data from the Multicenter AIDS Cohort Study (MACS) participants, we sought to investigate whether associations exist between kidney function and urine protein-to-creatinine ratio (UPCR) with CAC, and whether these associations differ by HIV serostatus.
Methods Population
The MACS is an ongoing prospective cohort study of the natural and treated history of HIV-1-infected men who have sex with men. From 1984 to 2003, 6972 men who have sex with men were enrolled at four sites: in Baltimore, Chicago, Pittsburgh, and Los Angeles [10] . The cohort includes both HIV-infected (HIV+ ) and HIV-uninfected (HIV− ) men who attend semiannual study visits that include standardized interviews, physical examinations, and blood and urine collection for laboratory testing and storage in local and central repositories.
Eligibility for the MACS cardiovascular ancillary study included being an active MACS participant, age 40-70 years, weight less than 300 lbs, and no previous history of cardiac surgery or percutaneous coronary intervention. All participants underwent noncontrast cardiac computed tomography (CT) scanning for CAC scoring. The study was approved by the Institutional Review Boards of all participating sites. All participants signed informed consent.
Computed tomography scanning and analysis procedures
Aspects of the noncontrast cardiac CT scanning procedures have been described previously [11] . The CT scanning equipment included a 64-slice multidetector CT at three centers and a 320-row multidetector CT at a fourth center. Images were transferred to the core CT reading center (Los Angeles Biomedical Research Institute at Harbor-UCLA) and were analyzed by trained, experienced readers who were blinded to participant characteristics and HIV serostatus. Calcification was quantified as described previously by Agatston et al. [12] .
Clinical parameters
During semiannual MACS visits, data were collected on coronary artery disease (CAD) risk factors and HIV clinical parameters by history, physical examination, and blood tests. Glomerular filtration rate (eGFR, ml/min/1.73 m 2 ) was estimated using the CKD-Epi equation [13] , and proteinuria was estimated using a UPCR measured from a spot urine sample. For the eGFR and UPCR, we used the average value from all visits within 1.5 years before the CT scan.
For the covariates, we used the value available from the visit closest to the CT scan, generally within 6 months. Race/ethnicity was based on self-report. Glucose, insulin, total and HDL cholesterol, and triglycerides were measured from fasting blood samples. For 15 men who did not provide fasting blood samples, total cholesterol and HDL were measured from nonfasting samples. LDL cholesterol was calculated using the Friedewald equation or measured directly in individuals with triglycerides more than 400 mg/dl or with nonfasting samples. Hypertension was defined as systolic blood pressure (BP) greater than or equal to 140 mmHg, diastolic BP greater than or equal to 90 mmHg, or self-reported use of antihypertensive medication among men with a history of hypertension. Diabetes mellitus was defined as a fasting serum glucose greater than or equal to 126 mg/dl or use of medications to treat diabetes among men with a history of diabetes. Measures of HIV disease activity included standardized testing of plasma HIV RNA levels [14] (Roche ultrasensitive assay with 50 copies/ml limit of detection; Roche Molecular Systems Inc., Branchburg, New Jersey, USA) [15] , CD4
+ T-lymphocyte cell counts (CD4) [16] , and a history of an AIDS-defining malignancy or opportunistic infection confirmed with medical record review. Also considered was current use of the HIV antiretrovirals abacavir or tenofovir disoproxil fumarate (tenofovir) as well as duration of highly active antiretroviral therapy use on the basis of self-reported information.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Statistical analyses
The distributions of demographic and clinical factors by HIV serostatus were compared using the Wilcoxon ranksum test for continuous variables and the Pearson's χ 2 -test for categorical variables.
Multiple logistic and linear regressions were used to evaluate associations of eGFR and UPCR with the (a) presence of CAC defined as a score above 0 and (b) the extent of CAC among men with a score above 0, respectively. The calcification score was natural-log transformed to normalize its distribution in analyses evaluating the extent of plaque. The effects of the exposure variables were described using piecewise linear splines for eGFR less than 90 and greater than or equal to 90 ml/min/1.73 m 2 (eGFR ≥ 90 ml/min/1.73 m 2 signifies normal kidney function) [17] and the natural logarithm of UPCR. To investigate whether these effects were modified by HIV infection, interaction terms between the exposure variables and HIV serostatus were assessed. Nonsignificant interaction terms were subsequently excluded from the model to obtain the overall effect of exposure variables that correspond to the excluded interaction effects.
All models were initially adjusted for age and race, and then further adjusted for CVD risk factors (BMI, systolic BP, use of hypertension medications, use of diabetes medications, fasting glucose, total and HDL cholesterol, use of lipid-lowering medications, and pack-years of tobacco smoking).
Multiple imputation was performed by HIV serostatus on missing CVD risk factor data for the analyses. The imputation models included the outcome, all predictors, and auxiliary variables (tobacco use and post-CT-scan use of lipid medications) that were strongly correlated with predictors that had the highest percentage of missing data. HIV-related factors (use of tenofovir or abacavir, history of AIDS, detectable plasma HIV RNA level, duration of highly active antiretroviral therapy, CD4 nadir, and current CD4) were also included in the imputation model for HIV+ men. Ten imputed data sets were produced for each HIV+ and HIV− participant using a Markov Chain Monte Carlo method assuming multivariate normality.
Values for the following numbers of men were missing and imputed for multiple regression analyses -hypertension medications (6), BMI (9), diabetes medications (10), smoking pack-years (29), lipid medications (22), total and HDL cholesterol (22) , systolic BP (6), and fasting glucose (21) .
All significance tests were at the 0.05 level and all analyses were carried out using SAS 9.2 (SAS Institute, Cary, North Carolina, USA).
Results
The 592 HIV+ and 378 HIV− men differed significantly by age, race, and risk factors for CVD ( 2 ) men (P = 0.37). The median UPCR was higher among HIV+ men compared with HIV− men (105.7, IQR: 76.7-158.3 vs. 67.5, IQR: 55.0-87.0; P < 0.0001). The prevalence of CAC was also similar between the two groups: 52.4% of HIV+ men had CAC compared with 51.8% of HIV− men (P = 0.88). Figure 1 compares the coefficient estimates adjusted for age and race between HIV− and HIV+ men. Associations of eGFR and UPCR with the prevalence and extent of CAC are in the same direction for both groups, with the exception of that between eGFR above 90 ml/min/1.73 m 2 and the extent of CAC. However, these associations are generally stronger among HIV− men compared with HIV+ men. This trend persists and estimates were practically the same after adjusting further for CVD risk factors (Tables 2 and 3 UPCR was not significantly associated with the prevalence of CAC. However, among men with CAC present, higher UPCR values were associated with greater CAC extent with a 0.32 (95% CI: 0.10-0.55) change in log CAC score per 1% increase in UPCR. There was a strong trend for modification by HIV serostatus for this association. Among HIV− men, there was a 0.75 (95% CI: 0.26-1.25) change in the log CAC score per 1% increase in UPCR. Conversely, among HIV+ men, each 1%
higher UPCR was associated with a 0.22 (95% CI: − 0.03 to 0.47) change in the log CAC score. The interaction by HIV serostatus, however, did not quite reach statistical significance (P = 0.06).
Discussion
Decreasing estimated glomerular filtration rate and coronary artery calcium
In the MACS, we found that among HIV+ and HIV− men with eGFRs below 90 ml/min/1.73 m 2 , the prevalence of CAC increased with lower eGFRs. To our knowledge, this is the largest population studied to date (n = 970) in which increased CAC prevalence has been found in association with lower Glomerular filtration rates (GFRs), even among individuals with mild kidney dysfunction (i.e. eGFRs between 60 and 90 ml/min/1.73 m 2 ), and confirms the previous findings of Roy et al. [2] (544 patients), Russo et al. [18] (140 patients), and Piers et al. [19] (83 patients) in smaller populations.
Our study prominently included many HIV + individuals, a group known to be at increased risk for both CVD Association of coronary artery calcium with proteinuria and eGFR levels, by HIV serostatus, among men in the MACS. (a) The prevalence and 95% confidence interval of CAC > 0 associated with a 1 U increase in UPCR, a 10 U decrease in eGFR among participants with eGFR < 90, and a 10 U decrease in eGFR among participants with eGFR ≥ 90, respectively, adjusting for age and race. (b) The extent of CAC (Agatston score) associated with a 1 U increase in UPCR, a 10 U decrease in eGFR among participants with eGFR < 90, and a 10 U decrease in eGFR among participants with eGFR ≥ 90, respectively, adjusting for age and race. CAC, coronary artery calcium; eGFR, estimated glomerular filtration rate; MACS, Multicenter AIDS Cohort Study; UPCR, urine protein-to-creatinine ratio. The results from the fully adjusted multiple logistic regression model are adjusted for age, race, and CAD risk factors (BMI, systolic BP, use of hypertension medications, use of diabetes medications, fasting glucose, total and HDL cholesterol, use of lipid-lowering medications, and pack-years of tobacco smoking) (N = 970). BP, blood pressure; CAD, coronary artery disease; CI, confidence interval; eGFR, estimated glomerular filtration rate; UPCR, urine protein-to-creatinine ratio. The results from the fully adjusted multiple linear regression model are adjusted for age, race, and CAD risk factors (BMI, systolic BP, use of hypertension medications, use of diabetes medications, fasting glucose, total and HDL cholesterol, use of lipid-lowering medications, and pack-years of tobacco smoking) (N = 506).
Bold indicates significant at 0.05 level. BP, blood pressure; CAC, coronary artery calcium; CAD, coronary artery disease; CI, confidence interval; eGFR, estimated glomerular filtration rate; UPCR, urine proteinto-creatinine ratio.
a Mean difference in the log CAC score per change in exposure variable.
and kidney disease. The inclusion of both HIV+ and HIV− men enabled us to investigate how HIV infection modifies the relationship between kidney disease and the presence and extent of CAC; we believe that ours is the first study to evaluate such HIV serostatus-based differences.
Recently published data from the MACS suggest that HIV infection predisposes preferentially to noncalcified, rather than calcified, plaque [20] , and accordingly, we found no significant HIV serostatus-based differences in the associations between eGFR and CAC prevalence. HIV infection itself may increase the risk for CVD through adverse effects from chronic inflammation, immune activation, and use of specific antiretroviral treatments that may increase the risk for CVD by causing proatherogenic dyslipidemia, insulin resistance, and body habitus changes that are linked to coronary atherogenesis [21] . CKD, however, may lead to increased CAD because of its pathogenic role in hypertension [22] , dyslipidemia [23] , systemic inflammation [24, 25] , as well as altered calcium and phosphorous homeostasis [26] . Our observation that impaired kidney function is a potential contributor toward the increased prevalence of CAC among HIV+ individuals, distinct from HIV itself, is novel.
Urine protein-to-creatinine ratio and coronary artery calcium
Albuminuria, a sign of endothelial dysfunction, is a known predictor of and marker for both CVD and CKD [27] . Proteinuria, which includes albuminuria as well as other urinary proteins, was associated significantly with greater CAC extent in those with CAC present among our total study population. A previous study by Jassal et al. [28] carried out in a smaller population of community-dwelling older adults (421 participants) did not show a correlation between albuminuria or eGFR and CAC severity or progression, but our study affirms a larger study (by Park et al. [29] ) involving 1318 asymptomatic, nonhypertensive, nondiabetic adults that showed a correlation between microalbuminuria and increased CAC.
Among HIV− individuals, proteinuria generally reflects albuminuria from endothelial dysfunction [30] , whereas among HIV+ infected individuals, there are additional causes of proteinuria, which include the pathognomonic HIV-associated nephropathy caused by HIV itself as well as renal tubular dysfunction that may occur from exposure to certain antiretroviral medications [31] . In subgroup analyses, we found a significant association between proteinuria and CAC extent among HIV− men, but not HIV+ men. Although our differential findings by HIV serostatus did not quite reach statistical significance, which may be explained by the lack of statistical power, they suggest the possibility that the clearer association between proteinuria and CAC extent among HIV− men reflects greater uniformity in the pathogenesis of proteinuria in this patient group -a group for whom the causes of proteinuria (largely albuminuria) such as diabetes and hypertension are clearly associated with CVD. In contrast, causes of proteinuria among HIV+ individuals are more diverse and include tubular proteinuria associated with specific antiretroviral medications use or other causes that are not clearly associated with CVD, as shown by Sarnak et al. [32] .
Study limitations
Roy et al. [2] and Budoff et al. [3] previously showed that lower GFR among individuals with CKD is associated with increased CAC extent. We also found significantly increased CAC extent with decreased eGFR among HIV− men without CKD. However, in contrast to the findings of these previous studies, in the current study, we did not observe a greater extent of CAC in association with decreased GFR in men with CKD or in HIV+ men with eGFR greater than or equal to 90 ml/min/1.73 m 2 .
These findings may reflect the fact that in the current study, we studied a somewhat younger population with earlier stages of kidney dysfunction and an overall lower prevalence of CAC factors that limited our ability to show an association between greater CAC extent and lower GFR. Among participants with preserved kidney function, perhaps there were not sufficient numbers of HIV+ individuals to show increased CAC severity associated with decreased eGFR.
Proteinuria was not associated independently with increased CAC prevalence in our study population, in contrast to previously reported findings from a much larger patient population (6814 patients, Defilippis et al. [5] ). However, our population may not have been sufficiently large to show this correlation.
As our study only included men, the generalizability of the findings to other risk groups may be limited. Furthermore, our data are based on subclinical coronary disease; thus, our findings require correlation with clinical cardiovascular outcomes over time.
Conclusion
In the MACS, lower eGFR (<90 ml/min/1.73 m 2 ) was associated significantly with increased CAC prevalence. Furthermore, proteinuria (increased UPCR) was significantly associated with greater CAC extent; there were borderline significant differences by HIV serostatus for this observation, with a clearer proteinuria/CAC extent relationship apparent for HIV− individuals. The clinical significance of these findings requires further prospective study to determine correlations between CKD, proteinuria, HIV infection, and cardiovascular clinical events.
